Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.75 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.75 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.66 |
| ▸ | ITGAV | P06756 | 8/20 | 0.63 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.62 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31614099 | 0.95 | ITGB3 (0.69) | ITGB3ITGA2BCXCR4ITGAVITGB5 | |
| Trifluoroacetic Acid SCHEMBL30467217 | 0.95 | ITGB3 (0.69) | ITGB3ITGA2BCXCR4ITGAVITGB5 | |
| SCHEMBL17364341 | 0.93 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29366713 | 0.93 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL29488627 | 0.91 | ITGB3 (0.64) | ITGB3ITGA2BCXCR4ITGAVITGB5 | |
| SCHEMBL10049951 | 0.90 | ITGB3 (0.60) | ITGB3ITGA2BCXCR4ITGAVITGB5 | |
| Trifluoroacetic Acid SCHEMBL29992576 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL20917265 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL31294830 | 0.88 | ITGB3 (0.80) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29464836 | 0.85 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403216-B2 | Chemical modification of silk fibroin for fabrication of enzymatically crosslinked hydrogels with tunable gelation kinetics and bioactivity | TRUSTEES OF TUFTS COLLEGE (US) | 2025-09-02 | — | — | US | claimed |
| US-20240335571-A1 | PRE-TARGETING STRATEGIES FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-10-10 | — | — | US | claimed |
| US-20240238383-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIV OF LOWA RESEARCH FOUNDATION (US) | 2024-07-18 | — | — | US | claimed |
| US-12029798-B2 | Pre-targeting strategies for molecular imaging and/or radioimmunotherapy | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-07-09 | — | — | US | claimed |
| EP-4340894-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | University Of Iowa Research Foundation (US) | 2024-03-27 | — | — | EP | claimed |
| US-20240082459-A1 | CHEMICAL MODIFICATION OF SILK FIBROIN FOR FABRICATION OF ENZYMATICALLY CROSSLINKED HYDROGELS WITH TUNABLE GELATION KINETICS AND BIOACTIVITY | TRUSTEES OF TUFTS COLLEGE | 2024-03-14 | — | — | US | claimed |
| WO-2022246280-A1 | ANTI-OXIDANT CONTAINING PARTICLES AND METHODS OF USE | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-11-24 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12584112-B2 | Organoid tissue engineering | Ecolepol Ytechnique Federale de Lausanne (CH) | 2026-03-24 | — | — | US | disclosed |
| US-12440584-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12403216-B2 | Chemical modification of silk fibroin for fabrication of enzymatically crosslinked hydrogels with tunable gelation kinetics and bioactivity | TRUSTEES OF TUFTS COLLEGE (US) | 2025-09-02 | — | — | US | disclosed |
| CN-120189488-A | Application of mimic polypeptide containing fibrinogen RGD module in preparation of medicines for preventing and/or treating parkinsonism | 南方医科大学珠江医院 | 2025-06-24 | — | — | CN | disclosed |
| US-11603371-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-11549017-B2 | NIR to SWIR fluorescent compounds for imaging and detection | PERKINELMER HEALTH SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220378739-A1 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-12-01 | — | — | US | disclosed |
| US-11466063-B2 | Conjugated knottin mini-proteins containing non-natural amino acids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-11 | — | — | US | disclosed |
| EP-4065691-A1 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Board of Regents, The University of Texas System (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114929853-A | Natural killer cell immunotherapy for the treatment of glioblastoma and other cancers | 得克萨斯大学体系董事会 | 2022-08-19 | — | — | CN | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584112-B2 | Organoid tissue engineering | KIT, EPCAM, ALPG | ITGB3 19/4885ITGA2B 65/4885CXCR4 2474/4885 |
| US-12440584-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | ITGB3 458/4885ITGA2B 833/4885CXCR4 764/4885 |
| US-11603371-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | ITGB3 458/4885ITGA2B 833/4885CXCR4 764/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ITGB3 1125/4885ITGA2B 1286/4885CXCR4 4098/4885 |
| US-11549017-B2 | NIR to SWIR fluorescent compounds for imaging and detection | SMARCD1, SMARCE1, SMARCB1 | ITGB3 2647/4885ITGA2B 2333/4885CXCR4 3889/4885 |
| US-11466063-B2 | Conjugated knottin mini-proteins containing non-natural amino acids | ECPAS, ATRIP, ANPEP | ITGB3 216/4885ITGA2B 86/4885CXCR4 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.